0.29

By Targets:	Adenosine Receptor (1) AMPK (1) Apoptosis (7) Autophagy (4) Bacterial (2) Bcl-2 Family (1) Beta-lactamase (1) Biochemical Assay Reagents (1) Btk (1) CDK (1) CFTR (1) Cholinesterase (ChE) (2) ClpP (1) Dengue virus (1) DNA/RNA Synthesis (1) EGFR (5) Endogenous Metabolite (1) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (3) Flavivirus (1) FLT3 (4) GABA Receptor (2) Glucosidase (1) HCV (1) HCV Protease (1) HDAC (1) HIV Protease (1) IKK (1) Integrin (1) Interleukin Related (1) IRE1 (1) Isotope-Labeled Compounds (5) JNK (1) Melanocortin Receptor (2) mGluR (2) Microsomal Triglyceride Transfer Protein (MTP) (1) Monoamine Transporter (1) mTOR (1) Necroptosis (1) NF-κB (1) NOD-like Receptor (NLR) (1) Parasite (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) Phosphoglycerate Dehydrogenase (PHGDH) (1) PI3K (2) PIKfyve (1) Protease Activated Receptor (PAR) (1) Proton Pump (3) SARS-CoV (1) Src (1) TAM Receptor (4) TGF-β Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (1) Tyrosinase (1) VEGFR (1) YAP (1) γ-secretase (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (2) Endocrinology (1) Infection (7) Inflammation/Immunology (8) Metabolic Disease (8) Neurological Disease (9)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126288

ASTX029

4 Publications Verification

ERK Apoptosis Cancer

ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC₅₀: 2.7 nM). ASTX029 has anti-cancer activity .

ASTX029 4 Publications Verification	ERK Apoptosis	Cancer
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC₅₀: 2.7 nM). ASTX029 has anti-cancer activity .

HY-155537

*YK-029A*	EGFR	Cancer
YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFR ^T790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models .

HY-NP029

Human Sermu Albumin-RBITC HSA-RBITC	Biochemical Assay Reagents	Others
Human Sermu Albumin-RBITC (HSA-RBITC) is a kind of biological materials or organic compounds that are widely used in life science research .

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .

HY-120837

PZ-II-029	GABA Receptor	Neurological Disease
PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to α6β3γ2. PZ-II-029 shows anti-migraine effects .

HY-W011246

Velnacrine maleate HP 029; Hydroxytacrine maleate	Cholinesterase (ChE)	Neurological Disease
Velnacrine maleate (HP 029) is an orally active cholinesterase inhibitor that can be used for the research of Alzheimer's disease .

HY-163319

NCA029	ClpP Apoptosis	Cancer
NCA029 is a potent and selective homo sapiens caseinolytic protease P (HsClpP) activator with an EC₅₀ of 0.15 μM. NCA029 acts on HsClpP to activate an ATF3-dependent integrative stress response, leading to colon cancer cell death .

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-148189

Aldometanib 2 Publications Verification LXY-05-029	AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

HY-160170

Necrosis inhibitor 3

Necroptosis Cancer

Necrosis inhibitor 3 (compound B3) is a poteng inhibitor of necrosis, with the IC₅₀ value of 0.29 nM in HT29 cells .

Necrosis inhibitor 3	Necroptosis	Cancer
Necrosis inhibitor 3 (compound B3) is a poteng inhibitor of necrosis, with the IC₅₀ value of 0.29 nM in HT29 cells .

HY-132905

Antileishmanial agent-2	Parasite	Infection
Antileishmanial agent-2 shows submicromolar antileishmanial activity (IC₅₀ = 0.29 μM) and a very high selectivity index with respect to mammalian cells.

HY-12432A

Gilteritinib hemifumarate 20+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

HY-12432

Gilteritinib 20+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-N3202

Neolitsine (+)-Neolitsine	Others	Cardiovascular Disease
Neolitsine ((+)-Neolitsine) is a vasodilator. Neolitsine can be isolated from the herb Cassytha filiformis. Neolitsine exhibits significant vasodilatory effects on precontracted rat aortic preparations with an IC₅₀ of 0.29 μM .

HY-141865

Adenosine receptor antagonist 1	Adenosine Receptor	Cancer
Adenosine receptor antagonist 1 is a A2aR-selective antagonist with an IC₅₀ of 0.29 nM and displays 14-fold more selective for A2aR than A2bR.

HY-100763

Mcl1-IN-12

Bcl-2 Family Cancer

Mcl1-IN-12 (Compound F) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with K_is of 0.29 and 3.1 μM, respectively. Anti-tumor activity .

Mcl1-IN-12	Bcl-2 Family	Cancer
Mcl1-IN-12 (Compound F) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with K_is of 0.29 and 3.1 μM, respectively. Anti-tumor activity .

HY-12432S1

Gilteritinib-d8 ASP2215-d₈	FLT3 TAM Receptor	Cancer
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-P1215

HS024	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-P1215A

HS024 TFA	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-108555

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM. .

HY-161443

TEAD-IN-9	YAP	Cancer
TEAD-IN-9 (compound 17) is a TEAD1 inhibitor with an IC₅₀ of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .

HY-137502

ML267	Bacterial	Infection
ML267 a potent Sfp phosphopantetheinyl transferase (PPTases) inhibitor with an IC₅₀ of 0.29 μM. ML267 also inhibits AcpS-PPTase with an IC₅₀ of 8.1 μM. ML267 possesses specific Gram-positive-targeted bactericidal activities .

HY-111772A

(R)-Elexacaftor (R)-VX-445	CFTR	Inflammation/Immunology
(R)-Elexacaftor is an enantiomer of Elexacaftor (HY-111772). (R)-Elexacaftor is the Compound 37 from patent WO2018107100A1. (R)-Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR), the EC50 for CFTR dF508 is 0.29 uM .

HY-12432R

Gilteritinib (Standard)	FLT3 TAM Receptor	Cancer
Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-155211

mTOR inhibitor-13	mTOR PI3K	Cancer
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective mTOR inhibitor with an IC₅₀ of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC₅₀ of 119 nM .

HY-161310

Metallo-β-lactamase-IN-15	Beta-lactamase	Infection
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC₅₀ values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .

HY-100781A

L-AP4 L-APB	mGluR	Neurological Disease
L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

HY-100781B

L-AP4 monohydrate L-APB monohydrate	mGluR	Neurological Disease
L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

HY-100246

CI-1044 PD-189659	Phosphodiesterase (PDE)	Inflammation/Immunology
CI-1044 is an orally active PDE4 inhibitor with IC₅₀s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.

HY-107600

IQ-3 1 Publications Verification	JNK	Inflammation/Immunology
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively .

HY-13636

Fulvestrant Maximum Cited Publications 75 Publications Verification ICI 182780; ZD 9238; ZM 182780	Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-143293

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .

HY-161456

PHGDH-IN-5	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC₅₀ value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .

HY-13898

Taselisib 15+ Cited Publications GDC-0032; RG-7604	PI3K	Cancer
Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-12164

Mocetinostat 10+ Cited Publications MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.

HY-13636S

Fulvestrant-d3 ICI 182780-d₃; ZD 9238-d₃; ZM 182780-d₃	Isotope-Labeled Compounds Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].

HY-13636R

Fulvestrant (Standard) Maximum Cited Publications 75 Publications Verification ICI 182780(Standard); ZD 9238(Standard); ZM 182780 (Standard)	Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant (Standard) is the analytical standard of Fulvestrant. This product is intended for research and analytical applications. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-W062835A

CGP77675 hydrate	Src	Cancer
CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity .

HY-133012

GFB-8438	TRP Channel	Neurological Disease
GFB-8438 is a potent and subtype selective TRPC5 inhibitor, with IC₅₀s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .

HY-151534

PBRM1-BD2-IN-7	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-7 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-7 has inhibitory activity for PBRM1-BD2 with an IC₅₀ value of 0.29 μM. PBRM1-BD2-IN-7 can be used for the research of cancer .

HY-161579

NLRP3-IN-39	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
NLRP3-IN-39 (Compound 49) inhibits the assembly and activation of NLRP3 inflammatory vesicles. NLRP3-IN-39 exerts its inhibitory effect by covalently binding to Cys 279 of the NLRP3 protein. NLRP3-IN-39 inhibits Nigericin (HY-127019)-induced IL-1β release from THP-1 cells (IC₅₀= 0.29 μM) .

HY-149340

PD07	Cholinesterase (ChE)	Neurological Disease
PD07 is an orally active AChE inhibitor (IC₅₀: 0.29 μM for hAChE). PD07 also inhibits ChEs, BACE1 (IC₅₀: 13.42 μM), and Aβ_1–42 aggregation in in vitro. PD07 is an antioxidant, and shows DPPH inhibitory activity (IC₅₀: 26.46 μM). PD07 improves memory and cognition in Scopolamine (HY-N0296)-induced amnesia rats. PD07 can be used for research of Alzheimer’s disease .

HY-104040

MKC8866 5+ Cited Publications Orin1001	IRE1	Cancer
MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC₅₀ of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC₅₀ of 0.52 μM and unstresses RPMI 8226 cells with an IC₅₀ of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .

HY-112823B

Almonertinib hydrochloride 3 Publications Verification HS-10296 hydrochloride	EGFR	Cancer
Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer .

HY-112823

Almonertinib 3 Publications Verification HS-10296	EGFR	Cancer
Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer .

HY-112823A

Almonertinib mesylate 3 Publications Verification HS-10296 mesylate	EGFR	Cancer
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .

HY-150683

NC-III-49-1	Epigenetic Reader Domain	Cancer
NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K_d values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc .

HY-19306

SB-267268	Integrin	Cancer
SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with K_is of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC₅₀s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression .

HY-149936

HIV-1 protease-IN-8	HIV Protease	Infection
HIV-1 protease-IN-8 (compound 34b) is a potent HIV-1 protease inhibitor with an IC₅₀ value of 0.32 nM. HIV-1 protease-IN-8 displays IC₅₀s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1_NL4-3) and drug-resistant variant (HIV-1_MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant .

Cat. No.	Product Name

HY-L029

Autophagy Compound Library

1,385 compounds

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.

MCE provides a unique collection of 1,385 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

Cat. No.	Product Name	Type

HY-NP029

Human Sermu Albumin-RBITC HSA-RBITC	Native Proteins
Human Sermu Albumin-RBITC (HSA-RBITC) is a kind of biological materials or organic compounds that are widely used in life science research .

Cat. No.	Product Name	Target	Research Area

HY-P1215A

HS024 TFA	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-P1215

HS024	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

Cat. No.	Product Name	Target	Research Area

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-P990240

Anti-Mouse GITR (LALA-PG) Antibody (DTA-1-CP029)	Inhibitory Antibodies	Others
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1-CP029) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse GITR.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3202

Neolitsine (+)-Neolitsine	Structural Classification Alkaloids Piperidine Alkaloids other families Hernandia nymphaeifolia (C. Presl) Kubitzki Source classification Plants	Others
Neolitsine ((+)-Neolitsine) is a vasodilator. Neolitsine can be isolated from the herb Cassytha filiformis. Neolitsine exhibits significant vasodilatory effects on precontracted rat aortic preparations with an IC₅₀ of 0.29 μM .

HY-N3101

Pedalitin	Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Plants Disease Research Fields Endocrinology	Endogenous Metabolite Tyrosinase Glucosidase
Pedalitin is a inhibitor of tyrosinase（IC₅₀=0.28 mM） and α-glucosidase（IC₅₀=0.29 mM） .

Species:	Human (3)
Tag:	His (1) GST (1) Fc (1)
Source:	HEK293 (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71471

	HADHB Protein, Human (GST) 3-ketoacyl-CoA thiolase; Acetyl CoA acyltransferase; Acetyl-CoA acyltransferase; Beta ketothiolase; Beta-ketothiolase; ECHB; ECHB_HUMAN; HADH; Hadhb; beta subunit; Hydroxyacyl Coenzyme A (CoA) dehydrogenase beta subunit; MGC87480; MSTP 029; MSTP029; MTPB; TP beta; TP-beta; TPbeta; Trifunctional enzyme subunit beta; Trifunct	Human	E. coli
	HADHB protein is an important component of mitochondrial trifunctional enzymes and directs three decisive reactions in the mitochondrial β-oxidation pathway. This pathway is critical for generating energy across tissues, breaking down long-chain fatty acids into acetyl-CoA. HADHB Protein, Human (GST) is the recombinant human-derived HADHB protein, expressed by E. coli , with N-GST labeled tag. The total length of HADHB Protein, Human (GST) is 249 a.a., with molecular weight of ~53.8 kDa.

HY-P76117

	TSPAN8 Protein, Human (HEK293, His) Tetraspanin-8; Tspan-8; CO-029; TSPAN8; TM4SF3	Human	HEK293
	TSPAN8 is a cell surface glycoprotein that is complexed with integrins and belongs to the four-span protein family. It has four hydrophobic domains. TSPAN8 mediates extracellular signal transduction processes and regulates cell development, activation, growth, and movement. In addition, TSPAN8 is expressed in different cancers and has potential roles in cancer prognosis and targeted therapy. TSPAN8 Protein, Human (HEK293, His) is the recombinant human-derived TSPAN8 protein, expressed by HEK293 , with N-His, N-6*His labeled tag. The total length of TSPAN8 Protein, Human (HEK293, His) is 96 a.a., with molecular weight of ~17 & 13 kDa, respectively.

HY-P76118

	TSPAN8 Protein, Human (HEK293, Fc) Tetraspanin-8; Tspan-8; CO-029; TSPAN8; TM4SF3	Human	HEK293
	TSPAN8 is a cell surface glycoprotein that is complexed with integrins and belongs to the four-span protein family. It has four hydrophobic domains. TSPAN8 mediates extracellular signal transduction processes and regulates cell development, activation, growth, and movement. In addition, TSPAN8 is expressed in different cancers and has potential roles in cancer prognosis and targeted therapy. TSPAN8 Protein, Human (HEK293, Fc) is the recombinant human-derived TSPAN8 protein, expressed by HEK293 , with N-mFc labeled tag. The total length of TSPAN8 Protein, Human (HEK293, Fc) is 96 a.a., with molecular weight of ~46 kDa.

Cat. No.	Product Name	Chemical Structure

HY-12432S1

Gilteritinib-d8

Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-13636S

Fulvestrant-d3
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].

HY-127165S2

Velnacrine-d4 hydrochloride

Velnacrine-d₄ (hydrochloride) is deuterium labeled Velnacrine.
HY-127165S1

Velnacrine-d3 maleate

Velnacrine-d₃ (maleate) is the deuterium labeled Velnacrine maleate[1].
HY-127165S

Velnacrine-d3

Velnacrine-d₃ is the deuterium labeled Velnacrine[1].
HY-127165S3

Velnacrine-d4

Velnacrine-d₄ is deuterium labeled Velnacrine.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81413

ARID1A Antibody (YA1158)

ARID1A; BAF250; C1orf4; ELD; HOSA1; Osa homolog 1; OSA1 nuclear protein; SMARCF1; MRD14; p270; B120; BM029
IHC-P Human


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies